HSRT and IMRT Chemoradiotherapy for Newly Diagnosed GBM

Inclusion Criteria: 1. 18-70 years of age; 2. Karnofsky performance status (KPS) ≥ 60 within 14 days prior to registration; 3. Histopathologically proved diagnosis glioblastoma multiforme; 4. Underwent surgery, gross total resection or subtotal resection; 5. Estimated survival of at least 3 months; 6. Hgb \> 90/gL; absolute neutrophil count (ANC) \> 1.5×109/L, platelets \> 80×109/L; Creatinine \< 1.5 times the upper limit of laboratory normal value; Bilirubin \< 2 times the upper limit of laboratory normal value; serum glutamate pyruvate transaminase (SGPT) or serum glutamate oxaloacetate transaminase (SGOT) \< 3 times the upper limit of laboratory normal value; 7. Signed informed consent form; 8. Agreed to participate in the follow-up. Exclusion Criteria: 1. Prior invasive malignancy unless disease free; 2. Received irradiation or other anti-tumor adjuvant therapies; 3. Brain stem disease or tumor greater than 6 cm in maximum diameter; 4. Prior therapy with an inhibitor of vascular endothelial growth factor (VEGF) or VEGFR; 5. Pregnancy or nursing mothers; 6. Participated in other trials after diagnosis; 7. Influence factors toward oral medications; 8. Patients with CTCAE5.0 grade 3+ bleeding within 4 weeks prior to registration; 9. Suffering from severe cardiovascular disease: myocardial ischemia or myocardial infarction above grade II, poorly controlled arrhythmias (including men with QTc interval ≥ 450 ms, women ≥ 470 ms); according to NYHA criteria, grades III to IV Insufficient function, or cardiac color Doppler ultrasound examination indicates left ventricular ejection fraction (LVEF) \<50%; 10. Long-term unhealed wounds or fractures; 11. History of organ transplantation; 12. Serious diseases that endanger patients' safety or affect patients' completion of research, according to the researchers' judgment.